|
Home:
Educational
Supplement: Section 8
SELECT PUBLICATIONS
Baselga J. Clinical
trials of Herceptin(trastuzumab). Eur J Cancer 2001;37
Suppl 1:S18-24. Abstract
Baselga J et
al. Phase II study of weekly intravenous trastuzumab (Herceptin)
in patients with HER2/neu-overexpressing metastatic breast cancer.
Semin Oncol 1999;26:78-83. Abstract
Berry DA et
al. HER-2/neu and p53 expression versus tamoxifen resistance
in estrogen receptor-positive, node-positive breast cancer.
J Clin Oncol 2000;18:3471-3479. Abstract
Burris HA 3rd.
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Semin Oncol 2001;28:38-44. Abstract
Burstein HJ
et al. Clinical activity of trastuzumab and vinorelbine in women
with HER2-overexpressing metastatic breast cancer. J Clin
Oncol 2001;19:2722-30. Abstract
Burstein HJ
et al. Preoperative Herceptin and paxlitaxel (Taxol) for HER2
overexpressing (HER2+) stage II/III breast cancer. Proc ASCO
2001;Abstract
100.
Carey LA et
al. Safety and efficacy of 4AC followed by paclitaxel plus trastuzumab
in high risk breast cancer patients. Proc ASCO 2001;Abstract
1856.
Cobleigh MA
et al. Multinational study of the efficacy and safety of humanized
anti-HER2 monoclonal antibody in women who have HER2-overexpressing
metastatic breast cancer that has progressed after chemotherapy
for metastatic disease. J Clin Oncol 1999;17:2639- 2648.
Abstract
Couturier J
et al. Strong correlation between results of Fluorescent in situ
hybridization and immunohistochemistry for the assessment of the
ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol
2000;13(11):1238-1243. Abstract
Horton J. HER2
and trastuzumab in breast cancer. Cancer Control 2001;8(1):103-110.
Full-Text
Jacobs TW et
al. Comparison of fluorescence in situ hybridization and immunohistochemistry
for the evaluation of HER-2/neu in breast cancer. J Clin
Oncol 1999;17:1974-1982. Abstract
Knoop AS et
al. Value of epidermal growth factor receptor, HER2, p53, and
steroid receptors in predicting the efficacy of tamoxifen in high-risk
postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376-3384.
Abstract
Lebeau A et
al. HER-2/neu analysis in archival tissue samples of human breast
cancer: Comparison of immunohistochemistry and fluorescence in situ
hybridization. J Clin Oncol 2001;19:354-363. Abstract
Mass R. The
role of HER-2 expression in predicting response to therapy in breast
cancer. Semin Oncol 2000;27(6 Suppl 11):46-52; discussion
92-100. Abstract
Mass RD et
al. Improved survival benefit from Herceptin (trastuzumab) in
patients selected by fluorescence in situ hybridization (FISH).
Proc ASCO 2001;Abstract
85.
Masood S, Bui
MM. Assessment of Her-2/neu overexpression in primary breast
cancers and their metastatic lesions: An immunohistochemical study.
Ann Clin Lab Sci 2000;30:259-65. Abstract
Nabholtz JM,
Slamon D. New adjuvant strategies for breast cancer: Meeting
the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Semin Oncol 2001;28:1-12. Abstract
Onody P et
al. Fluorescence in situ hybridization and immunohisto-chemical
assays for HER-2/neu status determination. Application to node-negative
breast cancer. Arch Pathol Lab Med 2001;125:746-750.
Abstract
Osoba D, Burchmore
M. Health-related quality of life in women with metastatic breast
cancer treated with trastuzumab (Herceptin). Semin Oncol
1999;26:84-8. Abstract
Paik S, Park
C. HER-2 and choice of adjuvant chemotherapy in breast cancer.
Semin Oncol 2001;28(4):332-5. Abstract
Pegram MD,
et al. Trastuzumab and chemotherapeutics: Drug interactions and
synergies. Semin Oncol 2000;27:21-5; discussion 92- 100.
Abstract
Pegram MD.
Docetaxel and herceptin: Foundation for future strategies.
Oncologist 2001;6 Suppl 3:22-5. Abstract
Pegram MD et
al. Phase II study of receptor-enhanced chemosensitivity using
recombinant humanized anti-p185HER2/neu monoclonal antibody plus
cisplatin in patients with HER2/neu-overexpressing metastatic breast
cancer refractory to chemotherapy treatment. J Clin Oncol
1998;16:2659-71. Abstract
Perez EA, Hortobagyi
GN. Ongoing and planned adjuvant trials with trastuzumab.
Semin Oncol 2000;27:26-32; discussion 92-100. Abstract
Persons DL
et al. Fluorescence in situ hybridization (FISH) for detection
of HER-2/neu amplification in breast cancer: A multicenter portability
study. Ann Clin Lab Sci 2000;30:41-8. Abstract
Ravdin PM.
Should HER2 status be routinely measured for all breast cancer
patients? Semin Oncol 1999;26(4 Suppl 12):117-23. Abstract
Seidman AD
et al. Weekly trastuzumab and paclitaxel therapy for metastatic
breast cancer with analysis of efficacy by HER2 immunophenotype
and gene amplification. J Clin Onco 2001;19:2587-95.
Abstract
Slamon DJ et
al. Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N
Engl J Med 2001;344:783-92. Abstract
Slamon D, Pegram
M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer
trials. Semin Oncol 2001;28:13-9. Abstract
Sparano JA.
Cardiac toxicity of trastuzumab (Herceptin): Implications for
the design of adjuvant trials. Semin Oncol 2001;28:20-7.
Abstract
Smith I. Future
directions in the adjuvant treatment of breast cancer: The role
of trastuzumab. Ann Oncol 2001;12(Suppl 1):S75-S79. Abstract
Tubbs RR et
al. Discrepancies in Clinical Laboratory Testing of Eligibility
for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives
Do Not Get the Message. J Clin Oncol 2001;19:2714- 2721.
Abstract
Vogel CL et
al. Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence
in situ hybridization (FISH)-selected patients. Proc ASCO
2001;Abstract
86.
Yamauchi H,
Stearns V, Hayes DF. When is a tumor marker ready for prime time?
A case study of c-erbB-2 as a predictive factor in breast cancer.
J Clin Oncol 2001;19:2334-56. Abstract
Top
Additional
Sections:
1 | 2
| 3 | 4
| 5 | 6
| 7 | 8
| 9 | 10
| 11 | 12
|
|
